Supplementary methods from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

MLA

Frédéric Amant, et al. Supplementary Methods from Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22466286.

APA

Frédéric Amant, Tjalling Bosse, Philippe Moerman, Els Hermans, Ellen Gommé, Debby Thomas, Godelieve Verbist, Miriam Mints, Eva Wardelmann, Michael R. Mallmann, Leonardus F. Massuger, Ronald P. Zweemer, Carole Mestdagh, Maciej Stukan, Helga B. Salvesen, Farid Moinfar, Johannes Haybaeck, Olli Carpén, Jutta Huvila, … Tine Cuppens. (2023). Supplementary methods from Potential Targets’ Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative. https://doi.org/10.1158/1078-0432.22466286

Chicago

Frédéric Amant, Tjalling Bosse, Philippe Moerman, Els Hermans, Ellen Gommé, Debby Thomas, Godelieve Verbist, et al. 2023. “Supplementary Methods from Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative,” March. doi:10.1158/1078-0432.22466286.